PMID- 37148547
OWN - NLM
STAT- MEDLINE
DCOM- 20230620
LR  - 20230912
IS  - 2045-7634 (Electronic)
IS  - 2045-7634 (Linking)
VI  - 12
IP  - 11
DP  - 2023 Jun
TI  - Sodium-glucose cotransporter 2 inhibitors versus dipeptidyl peptidase 4 
      inhibitors on new-onset overall cancer in Type 2 diabetes mellitus: A 
      population-based study.
PG  - 12299-12315
LID - 10.1002/cam4.5927 [doi]
AB  - BACKGROUND: Cancer is currently the second leading cause of death globally. There 
      is much uncertainty regarding the comparative risks of new-onset overall cancer 
      and pre-specified cancer for Type 2 diabetes mellitus (T2DM) patients on 
      sodium-glucose cotransporter 2 inhibitors (SGLT2I) versus DPP4I. METHODS: This 
      population-based cohort study patients included patients who were diagnosed with 
      T2DM and administered either SGLT2 or DPP4 inhibitors between 1 January 2015 and 
      31 December 2020 in public hospitals of Hong Kong. RESULTS: This study included 
      60,112 T2DM patients (mean baseline age: 62.1 +/- 12.4 years, male: 56.36%), of 
      which 18,167 patients were SGLT2I users and 41,945 patients were dipeptidyl 
      peptidase 4 inhibitor (DPP4I) users. Multivariable Cox regression found that 
      SGLT2I use was associated with lower risks of all-cause mortality (HR: 0.92; 95% 
      CI: 0.84-0.99; p= 0.04), cancer-related mortality (HR: 0.58; 95% CI: 0.42-0.80; 
      p </= 0.001) and new diagnoses of any cancer (HR: 0.70; 95% CI: 0.59-0.84; 
      p </= 0.001). SGLT2I use was associated with a lower risk of new-onset breast 
      cancer (HR: 0.51; 95% CI: 0.32-0.80; p </= 0.001), but not of other malignancies. 
      Subgroup analysis on the type of SGLT2I, dapagliflozin (HR: 0.78; 95% CI: 
      0.64-0.95; p = 0.01) and ertugliflozin (HR: 0.65; 95% CI: 0.43-0.98; p = 0.04) 
      use was associated with lower risks of new cancer diagnosis. Dapagliflozin use 
      was also linked to lower risks of breast cancer (HR: 0.48; 95% CI: 0.27-0.83; 
      p = 0.001). CONCLUSION: Sodium-glucose cotransporter 2 inhibitor use was 
      associated with lower risks of all-cause mortality, cancer-related mortality and 
      new-onset overall cancer compared to DPP4I use after propensity score matching 
      and multivariable adjustment.
CI  - (c) 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
FAU - Chung, Cheuk To
AU  - Chung CT
AD  - Diabetes Research Unit, Cardiovascular Analytics Group, China-UK Collaboration, 
      Hong Kong, China.
FAU - Lakhani, Ishan
AU  - Lakhani I
AD  - Diabetes Research Unit, Cardiovascular Analytics Group, China-UK Collaboration, 
      Hong Kong, China.
FAU - Chou, Oscar Hou In
AU  - Chou OHI
AD  - Diabetes Research Unit, Cardiovascular Analytics Group, China-UK Collaboration, 
      Hong Kong, China.
AD  - Division of Clinical Pharmacology and Therapeutics, Department of Medicine, LKS 
      Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
FAU - Lee, Teddy Tai Loy
AU  - Lee TTL
AD  - Diabetes Research Unit, Cardiovascular Analytics Group, China-UK Collaboration, 
      Hong Kong, China.
FAU - Dee, Edward Christopher
AU  - Dee EC
AD  - Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New 
      York, New York, USA.
FAU - Ng, Kenrick
AU  - Ng K
AD  - Department of Medical Oncology, University College London Hospitals NHS 
      Foundation Trust, London, UK.
FAU - Wong, Wing Tak
AU  - Wong WT
AD  - School of Life Sciences, Chinese University of Hong Kong, Hong Kong, China.
FAU - Liu, Tong
AU  - Liu T
AUID- ORCID: 0000-0003-0482-0738
AD  - Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, 
      Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of 
      Tianjin Medical University, Tianjin, China.
FAU - Lee, Sharen
AU  - Lee S
AD  - Diabetes Research Unit, Cardiovascular Analytics Group, China-UK Collaboration, 
      Hong Kong, China.
FAU - Zhang, Qingpeng
AU  - Zhang Q
AD  - School of Data Science, City University of Hong Kong, Hong Kong, China.
FAU - Cheung, Bernard Man Yung
AU  - Cheung BMY
AD  - Division of Clinical Pharmacology and Therapeutics, Department of Medicine, LKS 
      Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
FAU - Tse, Gary
AU  - Tse G
AD  - Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, 
      Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of 
      Tianjin Medical University, Tianjin, China.
AD  - Kent and Medway Medical School, University of Kent and Canterbury Christ Church 
      University, Canterbury, UK.
AD  - School of Nursing and Health Studies, Hong Kong Metropolitan University, Hong 
      Kong, China.
FAU - Zhou, Jiandong
AU  - Zhou J
AD  - Diabetes Research Unit, Cardiovascular Analytics Group, China-UK Collaboration, 
      Hong Kong, China.
AD  - Nuffield Department of Medicine, University of Oxford, Oxford, UK.
LA  - eng
GR  - P30 CA008748/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20230506
PL  - United States
TA  - Cancer Med
JT  - Cancer medicine
JID - 101595310
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 1ULL0QJ8UC (dapagliflozin)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - 0 (Hypoglycemic Agents)
RN  - IY9XDZ35W2 (Glucose)
RN  - 9NEZ333N27 (Sodium)
SB  - IM
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Aged
MH  - *Diabetes Mellitus, Type 2/drug therapy/epidemiology/complications
MH  - *Dipeptidyl-Peptidase IV Inhibitors/adverse effects
MH  - Cohort Studies
MH  - *Sodium-Glucose Transporter 2 Inhibitors/adverse effects
MH  - Treatment Outcome
MH  - Hypoglycemic Agents/therapeutic use
MH  - *Breast Neoplasms/complications
MH  - Glucose
MH  - Sodium
MH  - Retrospective Studies
PMC - PMC10278500
COIS- The authors declare no potential conflicts of interest.
EDAT- 2023/05/06 19:42
MHDA- 2023/06/20 06:42
PMCR- 2023/05/06
CRDT- 2023/05/06 15:35
PHST- 2023/03/07 00:00 [revised]
PHST- 2022/10/15 00:00 [received]
PHST- 2023/03/30 00:00 [accepted]
PHST- 2023/06/20 06:42 [medline]
PHST- 2023/05/06 19:42 [pubmed]
PHST- 2023/05/06 15:35 [entrez]
PHST- 2023/05/06 00:00 [pmc-release]
AID - CAM45927 [pii]
AID - 10.1002/cam4.5927 [doi]
PST - ppublish
SO  - Cancer Med. 2023 Jun;12(11):12299-12315. doi: 10.1002/cam4.5927. Epub 2023 May 6.